Heron Therapeutics 관리
관리 기준 확인 2/4
Heron Therapeutics CEO는 Craig Collard, Apr2023 에 임명되었습니다 의 임기는 1.58 년입니다. 는 $ 298.72K 가치에 해당하는 회사 주식의 0.18% 직접 소유합니다. 298.72K. 경영진과 이사회의 평균 재임 기간은 각각 1.4 년과 3.2 년입니다.
주요 정보
Craig Collard
최고 경영자
US$5.5k
총 보상
| CEO 급여 비율 | n/a |
| CEO 임기 | 1.6yrs |
| CEO 소유권 | 0.2% |
| 경영진 평균 재임 기간 | 1.4yrs |
| 이사회 평균 재임 기간 | 3.2yrs |
최근 관리 업데이트
Recent updates
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge
Nov 13
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%
Nov 13Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%
Aug 08Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
May 30Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Apr 16Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results
Mar 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%
Dec 22Heron wins FDA nod for post-operative agent to address nausea and vomiting
Sep 16Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?
Aug 10Heron Therapeutics Q2 2022 Earnings Preview
Aug 08Heron Therapeutics proposes 34% cut in workforce as part of cost reduction plan
Jun 30Heron Therapeutics: Cash Is A Problem Again
Mar 31Heron Therapeutics: Changing Strategy After Disappointing Earnings
Mar 03Health Check: How Prudently Does Heron Therapeutics (NASDAQ:HRTX) Use Debt?
Jan 19Heron Therapeutics: Looking For Signs Of The Bottom
Oct 07Is Heron Therapeutics (NASDAQ:HRTX) Using Too Much Debt?
Oct 03CEO
Craig Collard (58 yo)
1.6yrs
테뉴어
US$5,486
보상
Mr. Craig Alexander Collard serves as Chief Executive Officer at Heron Therapeutics, Inc. since April 3, 2023 and its Director since February 2023. He had been Chief Executive Officer of Veloxis Pharmaceut...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Director | 1.6yrs | US$5.49k | 0.18% $ 298.7k | |
| Executive VP & CFO | 1.4yrs | US$1.76m | 0.071% $ 121.0k | |
| Executive VP & Chief Development Officer | 1.4yrs | US$1.71m | 0.068% $ 115.5k | |
| Vice President of Marketing | 1.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Human Resources | 9.2yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Oncology Care Franchise & Commercial Operations | 1.8yrs | 데이터 없음 | 데이터 없음 | |
| Chief Business Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Executive Director | no data | 데이터 없음 | 데이터 없음 |
1.4yrs
평균 재임 기간
55yo
평균 연령
경험이 풍부한 관리: HRTX 의 관리팀은 경험 (평균 재직 기간 1.4 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$5.49k | 0.18% $ 298.7k | |
| Independent Director | 10.8yrs | US$11.02m | 0.034% $ 58.1k | |
| Independent Director | 8.4yrs | US$70.51k | 0.034% $ 58.5k | |
| Director | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 3.2yrs | US$65.63k | 0.035% $ 59.3k | |
| Independent Chairman | 1.8yrs | US$545.53k | 0.0062% $ 10.6k | |
| Independent Director | 3.2yrs | US$55.00k | 0.035% $ 59.3k |
3.2yrs
평균 재임 기간
57yo
평균 연령
경험이 풍부한 이사회: HRTX 의 이사회는 경험(평균 재직 기간 3.2 년)으로 간주됩니다.